Stock Analiz

Novo Nordisk A S (NVO) financials: revenue, earnings and cash flow

Fiscal 2019–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Novo Nordisk A S’s revenue went from $18.3B in fiscal 2019 to $48.6B in fiscal 2025, growth of about 17.6% a year.

Net income in fiscal 2025 was $16.1B, a net margin of 33.1%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $49.2B and net income $16.7B.

Free cash flow was $9.3B in fiscal 2025 and positive in 7 of the 7 years shown.

Revenue, profit and cash flow by year

Revenue
2019: $18.3B20192020: $20.9B20202021: $21.4B20212022: $25.4B20222023: $34.4B20232024: $40.5B20242025: $48.6B2025$48.6B
Net income
2019: $5.9B20192020: $6.9B20202021: $7.3B20212022: $8.0B20222023: $12.4B20232024: $14.1B20242025: $16.1B2025$16.1B
Free cash flow
2019: $5.7B20192020: $7.6B20202021: $7.4B20212022: $9.6B20222023: $12.3B20232024: $10.3B20242025: $9.3B2025$9.3B
EPS (diluted)
2019: $1.3220192020: $1.5720202021: $1.6420212022: $1.8020222023: $2.8020232024: $3.1820242025: $3.642025$3.64

Income statement

Fiscal yearTTM2025202420232022202120202019
Revenue$49.2B$48.6B$40.5B$34.4B$25.4B$21.4B$20.9B$18.3B
Gross profit—$39.4B$34.3B$29.1B$21.3B$17.8B$17.5B$15.3B
Operating income—$20.1B$17.9B$15.2B$10.7B$8.9B$8.9B$7.9B
Net income$16.7B$16.1B$14.1B$12.4B$8.0B$7.3B$6.9B$5.9B
EPS (diluted)$3.76$3.64$3.18$2.80$1.80$1.64$1.57$1.32
R&D————————
Revenue growth—+20.2%+17.5%+35.7%+18.4%+2.4%+14.1%—

Cash flow

Fiscal yearTTM2025202420232022202120202019
Operating cash flow$18.8B$18.7B$16.9B$16.1B$11.3B$8.4B$8.6B$7.0B
Capital spending-$12.1B-$9.5B-$6.6B-$3.8B-$1.7B-$965M-$961M-$1.3B
Free cash flow$6.6B$9.3B$10.3B$12.3B$9.6B$7.4B$7.6B$5.7B
Dividends paid$7.7B$8.1B$6.1B$4.7B$3.6B$3.3B$3.3B$2.9B
Buybacks—$218M$2.8B$4.4B$3.5B$3.0B$2.8B$2.3B
Stock-based pay—$226M$319M$319M$221M$158M$136M$55M

Balance sheet

Fiscal yearTTM2025202420232022202120202019
Cash—$4.2B$2.2B$2.1B$1.8B$1.6B$2.0B$2.3B
Debt—$20.6B$14.3B$4.0B$3.7B$4.1B$1.7B$674M
Equity—$30.5B$20.0B$15.8B$12.0B$10.8B$10.4B$8.7B
Total assets—$85.4B$64.9B$46.6B$34.6B$29.6B$23.9B—
Shares (diluted)4.44B4.43B4.43B4.43B4.43B4.43B4.43B4.43B

Margins and returns

Fiscal yearTTM2025202420232022202120202019
Gross margin—81.0%84.7%84.6%83.9%83.2%83.5%83.5%
Operating margin—41.3%44.2%44.2%42.3%41.6%42.6%43.0%
Net margin33.9%33.1%34.8%36.0%31.4%33.9%33.2%31.9%
FCF margin13.5%19.1%25.4%35.8%37.7%34.6%36.3%31.0%
ROIC—30.8%41.4%61.4%55.0%48.7%58.3%67.8%
ROE—52.8%70.4%78.5%66.5%67.5%66.5%67.6%

Frequently asked questions

What is Novo Nordisk A S’s annual revenue?

$48.6B in fiscal 2025 and $49.2B over the twelve months to September 30, 2026.

How much profit does Novo Nordisk A S make?

Net income was $16.1B in fiscal 2025 (net margin 33.1%).

Is Novo Nordisk A S’s revenue growing?

Yes: revenue rose 20.2% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.